0001209191-23-002635.txt : 20230109 0001209191-23-002635.hdr.sgml : 20230109 20230109184123 ACCESSION NUMBER: 0001209191-23-002635 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220722 FILED AS OF DATE: 20230109 DATE AS OF CHANGE: 20230109 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Stephenson Pamela CENTRAL INDEX KEY: 0001767650 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-33451 FILM NUMBER: 23519306 MAIL ADDRESS: STREET 1: C/O ZYNERBA PHARMACEUTICALS, INC. STREET 2: 80 W. LANCASTER AVENUE, SUITE 300 CITY: DEVON STATE: PA ZIP: 19333 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ALBIREO PHARMA, INC. CENTRAL INDEX KEY: 0001322505 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10 POST OFFICE SQUARE STREET 2: SUITE 502 SOUTH CITY: BOSTON STATE: MA ZIP: 02109 BUSINESS PHONE: 857-415-4774 MAIL ADDRESS: STREET 1: 10 POST OFFICE SQUARE STREET 2: SUITE 502 SOUTH CITY: BOSTON STATE: MA ZIP: 02109 FORMER COMPANY: FORMER CONFORMED NAME: Biodel Inc DATE OF NAME CHANGE: 20050331 4/A 1 doc4a.xml FORM 4/A SUBMISSION X0306 4/A 2022-07-22 2022-07-25 0 0001322505 ALBIREO PHARMA, INC. ALBO 0001767650 Stephenson Pamela C/O ALBIREO PHARMA, INC. 53 STATE STREET, 19TH FLOOR BOSTON MA 02109 0 1 0 0 Chief Commercial Officer Common Stock 2022-07-22 4 S 0 106 24.6713 D 45649 D Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.67 to $24.7431, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. Represents 15,923 shares of common stock and 29,726 restricted stock units. This amended Form 4 is being filed solely to correct the numbers of shares disclosed in column 5 of Table I and footnote 3, as the reporting person did not acquire 547 shares of common stock under the Albireo Pharma, Inc. 2018 Employee Stock Purchase Plan on May 31, 2022. /s/ Jason Duncan, Attorney-in-fact 2023-01-09